Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Gardner

Orthopaedic Surgery Fort Myers, FL Medical Doctor

NPI 1255334488 CMS profile 284150

3033 Winkler Ave Unit 100, Unit 100, Fort Myers, FL 33916

Open in the dashboard

General payments

$99,009

187 records reported · program years 2019–2025

Research payments

$28,050

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$1,849,522

4 holdings reported · through program year 2025

Through program year 2025, Ronald Gardner of Fort Myers, FL is reported in the CMS Open Payments database as having received $99,009 across 187 general payments and $28,050 in research payments paid to them. They also declared ownership or investment interests valued at $1,849,522 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,310 22
2024 General $19,225 34
2023 General $18,780 28
2022 General $9,052 23
2021 General $4,404 30
2020 General $413 13
2019 General $22,826 37
2019 Research $28,050 1
2022 Ownership $28,309 1
2021 Ownership $28,309 1
2020 Ownership $907,852 1
2019 Ownership $885,052 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Gardner
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Ronald Gardner were reported at $24,310. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Ronald Gardner Orthopaedic Surgery median Middle half National median
2019 $22,826 $644 $140–$2,844 $163
2020 $413 $312 $75–$1,860 $114
2021 $4,404 $520 $117–$2,495 $132
2022 $9,052 $598 $128–$2,731 $149
2023 $18,780 $461 $128–$2,264 $160
2024 $19,225 $497 $134–$2,475 $164
2025 $24,310 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shalby Advanced Technologies, Inc. $48,901 43 payments
  2. Consensus Orthopedics, Inc. $21,159 12 payments
  3. Aesculap Implant Systems, LLC $15,919 33 payments
  4. Avanos Medical $6,578 7 payments
  5. Curonix LLC $1,426 9 payments
  6. MicroPort Orthopedics Inc $912 6 payments
  7. SI-BONE, Inc. $626 11 payments
  8. Stryker Corporation $372 5 payments
  9. Medtronic, Inc. $315 3 payments
  10. LinkBio Corp $278 4 payments
  11. Other $2,524 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $73,957 19 payments
  2. Food and Beverage $7,535 140 payments
  3. Honoraria $6,288 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,769 1 payment
  5. Travel and Lodging $5,340 24 payments
  6. Education $121 2 payments
Products named General payments · program years 2019–2025
  1. CONSENSUS KNEE SYSTEM Orthopedics $20,857 15 payments
  2. CONSENSUS HIP SYSTEM $20,841 3 payments
  3. CONSENSUS KNEE SYSTEM Orthopedics $20,841 3 payments
  4. Consensus Knee System Orthopedics $10,400 14 payments
  5. Consensus Knee System Orthopedics $10,039 8 payments
  6. CKS - VitalitE Orthopedics $9,952 7 payments
  7. CKS - VitalitE Orthopedics $9,952 7 payments
  8. CKS - VitalitE Orthopedics $9,939 10 payments
  9. CKS - VitalitE Orthopedics $9,939 10 payments
  10. Consensus Knee System Orthopedics $9,939 10 payments
  11. Other $48,443 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ASA srl $28,050 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

3,752

Median for Orthopedic Surgery: 203

Drug cost

$39,973

Median for Orthopedic Surgery: $1,433

Branded share of claims

11.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 740 $19,151
Xarelto Rivaroxaban Brand 13 $3,227
Cephalexin Generic 578 $2,521
Oxycodone Hcl Generic 325 $2,239
Allopurinol Generic 229 $1,777
Meloxicam Generic 503 $1,420
Tramadol Hcl Generic 213 $1,374
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 99 $1,180
Ondansetron Odt Ondansetron Brand 161 $1,116
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 136 $765

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$403,099

Of which drugs: $3,842

Medicare patients

881

Average age 75

Services billed

4,728

568 women, 313 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Ischemic heart disease 30%
Diabetes 24%
Depression 24%
Osteoporosis 21%
Chronic kidney disease 20%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg J7332 Office 17 400 $3,213
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 24 25 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Exparel
  • Pacira Pharmaceuticals Incorporated $118
$118 — —
EVENITY
  • Amgen Inc. $16
$16 — —
Prolia
  • Amgen Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record